Novavax (NVAX) Payables (2010 - 2026)

Novavax's Payables history runs 17 years deep, the most recent figure standing at $16.1 million for Q1 2026.

• On a quarterly basis, Payables fell 52.87% year-over-year to $16.1 million in Q1 2026; TTM through Mar 2026 was $16.1 million, a 52.87% decrease from a year earlier, with the FY2025 full-year figure at $24.6 million, down 40.89% from the prior year.
• Payables slipped to $16.1 million in Q1 2026 per NVAX's latest filing, from $24.6 million in the prior quarter.
• Across five years, Payables topped out at $710.7 million in Q2 2022 and bottomed at $15.2 million in Q3 2025.
• The 5-year median for Payables is $80.0 million (2024), against an average of $176.7 million.
• Across the five-year window, Payables jumped 860.41% in 2022 and slumped 87.72% in 2023, its largest moves.
• Year by year, Payables stood at $541.4 million in 2022, then sank by 75.51% to $132.6 million in 2023, then slumped by 68.65% to $41.6 million in 2024, then plunged by 40.89% to $24.6 million in 2025, then tumbled by 34.49% to $16.1 million in 2026.
• Per Business Quant, the three latest NVAX Payables figures stand at $16.1 million (Q1 2026), $24.6 million (Q4 2025), and $15.2 million (Q3 2025).